Exscientia, a pioneering force in the field of artificial intelligence-driven drug discovery, is headquartered in the United Kingdom. Founded in 2012, the company has rapidly established itself as a leader in the biotechnology industry, focusing on the integration of AI with traditional pharmaceutical development processes. With a strong operational presence in Europe and North America, Exscientia is renowned for its unique approach to designing and optimising drug candidates, significantly reducing the time and cost associated with bringing new therapies to market. The company’s core services include AI-based drug design and precision medicine, which leverage advanced algorithms to enhance the efficiency of drug discovery. Exscientia's notable achievements include collaborations with major pharmaceutical companies and a robust pipeline of drug candidates, positioning it as a key player in the evolving landscape of drug development.
We don't have data for Exscientia, but we can show you information about their parent organization instead.
View parent company